Athersys (ATHX) +200% after inking a deal with Pfizer (PFE) to develop and market its...

|By:, SA News Editor

Athersys (ATHX) +200% after inking a deal with Pfizer (PFE) to develop and market its experimental stem cell therapy MultiStem. Pfizer will pay $6M up front, fund the drug's R&D, and pay up to $105M on milestones.